Meridian Management Co. Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Meridian Management Co. lessened its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,070 shares of the biopharmaceutical company’s stock after selling 8,297 shares during the quarter. Meridian Management Co.’s holdings in Pfizer were worth $691,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at approximately $36,000. DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $37,000. Finally, Life Planning Partners Inc acquired a new position in Pfizer during the 4th quarter valued at approximately $39,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3 %

Shares of PFE traded up $0.07 during trading on Thursday, reaching $27.89. 5,343,437 shares of the company traded hands, compared to its average volume of 41,726,629. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock has a market cap of $158.04 billion, a PE ratio of -464.92, a price-to-earnings-growth ratio of 1.11 and a beta of 0.63. The stock has a 50-day simple moving average of $27.31 and a 200-day simple moving average of $27.90. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the firm posted $1.23 earnings per share. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.02%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $35.86.

View Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.